I didn't ask for all that information, but thank you for sharing your opinion. I have read the RNS myself and am aware it doesn't mention figures, I have looked into what Med Rhythms concept is and I think it's very interesting. It's just a shame they haven't disclosed the other company as I like to look into what they do exactly so hopefully they'll disclose that at some point. Good night all :)
New contracts sound promising. I've just had a look into the Med Rhythms website and its a great addition to the contracts 7dig already have. But does anyone have any ideas what the second company is reg treating dementia? I can't see it named.
I certainly wouldn't buy your shares as it would be a rubbish average for me buying at 0.19. I'm confident we'll see those highs again, but buying on a spike is never a good idea.
Thanks for the info. My dad died of covid a few weeks ago and I know they struggled to control his blood sugars and he had diabetes. Very interesting, I really hope they manage to help others with this drug as its a truly terrible virus to succumb to. Stay safe everyone.
Thank you for sharing the Telegraph article. Previous RNS stated we'd hopefully have 150 patients by the end of February and the results assessed for the month of March. Is it possible they might have to extend this as it seems unlikely we'll recruit 68 patients in 10 days?
When are we expecting results? Thank you
It would be foolish to sell with the new investment being listed tomorrow. I can see us holding 0.09 today.
Also we aren't going to get to 1p in one day? A more reasonable target is 0.10-0.12 at the moment for the next few days.
We have to remember though at the moment the investments are good, but they need to deliver. We can't expect the sp to hold until we have something concrete.
The way I see it Mode is relatively new, the SGS trial is results dependent and the Kanabo company is going to be newly listed in February. So these are all in the early stages, but once they start taking off who knows. We have a good diversity with the investments we currently have and I don't know about anyone else but I'm very excited to see what they invest the remaining money with.
I'm not sure what response velastic said, but I think a decent sp would be 0.50 if trial results are according to plan, I know Vela had a broker target of 2.5p and that was before the current investments of the SGS trial and the Kanabo investment so we are really overdue an updated target.
More about the device and testing results reg dosing accuracy and byproducts produced when heated.
Dosing accuracy
The ability to replicate the same dose engenders trust in our device. The VapePod is able to offer a dose with consistent accuracy of 1.2 mg
The results of our tests concluded that the battery was able to replicate each inhalation with the same amount of vapor.
Testing device when heated
We provide our consumers with a specially designed formula that has no variation when heated. Further building Kanabo’s standard of quality, the vapor is then tested for consistency as heating has the potential to unlock unwanted byproducts.
The result of our tests concluded that the quality of the vapor produced by the VapePod remained consistent with little to an insignificant amount of byproducts. No matter how full or depleted the cartridge was, the vapor remained consistent both in cannabinoids and terpenoid composition.
It is not just a vape pen. It is significant in that this is the first medically licensed vaporizer. Its also significant that unlike a vape pen it is designed to give a specific amount of treatment based on a prescription.
These products are not going to be bought in a vape shop, but prescribed for medical conditions.
https://www.kanabogroup.com/device/
It's also rather interesting that many illegally buy vaporizing devices that contain harmful additives, this is the real stuff with nothing harmful added.
Some more information about the types of conditions potentially that can be treated.
Potential Targeted Conditions Chronic Pain
Structural disorders – brain or spinal cord injury/trauma, tumors, or neuropathy. Functional disorders – headache, fibromyalgia. Other disorders – arthritis, shingles, central pain syndrome.
Anxiety Disorders: Post Traumatic Stress Disorder (PTSD) Obsessive Compulsive Disorder (OCD) Panic Disorder
Sleep Disorders: Potential Targeted Conditions
Sleep disorders – insomnia, restless legs syndrome (RLS), or periodic limb movement disorder (PLMD). Structural disorders – brain or spinal cord injury/trauma, tumors, or neuropathy. Functional disorders – headache, neuralgia, or fibromyalgia.
Vela has invested in Kanabo, an Israel based research and development company which currently sells a range of THC-free retail cannabidiol (CBD) products. Its detailed in the RNS which was announced today.
The interesting thing about it is the fact it is they have designed a inhalation device. It's not just simply what most other companies are doing which is supplying the cannabis this is a product.
For anyone wanting to know more about new investment this is a good watch.
https://youtu.be/NOAzFsi1750